Basic Science / Clinical Interface Sessions: Pathways to Progress

Emerging Targets in the Wnt Pathway

A wnt-wnt situation: Novel therapeutic targets for cancer
Kathleen H. Goss

Wnt signaling and disease and development
Michael Kahn, University of Southern California, Los Angeles, CA

Small molecule-mediated description of Wnt signal transduction pathways
Lawrence G. Lum, Barbara Ann Karmanos Cancer Institute, Detroit, MI

Genetic Malformation Syndromes and Malignancy

Congenital syndromes and cancer: From syndrome recognition to intervention
Gail E. Tomlinson

Use of array comparative genomic hybridization to identify new cancer susceptibility genes and syndromes
Sharon E. Plon, Baylor College of Medicine, Houston, TX

Histone Deacetylases as Targets of Cancer Therapy

HDACs: An overview
Edward Seto

Development of histone deacetylase inhibitors as cancer therapeutics
Ricky W. Johnstone, Peter MacCallum Cancer Institute, East Melbourne, Australia

Vorinostat: Preclinical and clinical experience
Christian Steinkuhler, Merck and Co., Pomezia, Italy

HSP90 Inhibition for HER2 Positive Breast Cancer and Other Malignancies

HSP90: What is the pathway?
Leonard M. Neckers, National Cancer Institute, Rockville, MD

Challenges in translating HSP90 inhibition to the clinic
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY

HSP90 inhibitors for HER2 positive breast cancer: Proof of principle
Clifford A. Hudis

Chemokines and Cancer

Chemokines as a key component of cancer-related inflammation
Alberto Mantovani

Optimal mobilization of normal and leukemic stem cells via modulation of chemokine and integrin axes
John F. DiPersio, Washington University School of Medicine, St. Louis, MO

Targeting the chemokine system in ovarian cancer
Kenneth J. Pienta, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Forkhead Box Proteins in Cancer

FoxO proteins: The fork of the roads
Tak W. Mak

FoxOs in cancer and aging
Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA

The role of FoxO family members in hematopoiesis and cancer
Dwight Gary Gilliland, Harvard Medical School, Boston, MA

Therapeutic Targeting of ras Pathways

The ras pathway in carcinogenesis
David A. Tuveson

Feedback loops in the ras pathway: Implications for targeted therapy
Frank McCormick, University of California Comprehensive Cancer Center, San Francisco, CA

Targeting mutant KRAS tumors with combined inhibition of RAS effector pathways
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

DNA Repair Proteins as Molecular Targets for Cancer Therapeutics

Overview of DNA repair targets for the treatment of cancer
Mark R. Kelley

From concept to clinical trials: Evaluation of poly (ADP-ribose) polymerase inhibitor preclinical data and its use in the design of clinical trials
Vincent L. Giranda, Abbott Laboratories, Abbott Park, IL

Chemopotentiation by manipulation of DNA repair: An update on the clinical status and potential emerging therapies
Elizabeth R. Plummer, University of Newcastle, Newcastle Upon Tyne, United Kingdom

Hedgehog Signaling Antagonists for Cancer Therapeutics

Hedgehog signaling antagonists for cancer therapeutics
Jingwu Xie

Hedgehog signaling and pancreatic cancer
Matthias Hebrok, University of California, San Francisco, CA, and Anirban Maitra, Johns Hopkins University School of Medicine, Baltimore, MD

Specific hedgehog signaling antagonists and their implications in cancer treatment
Frederic J. de Sauvage, Genentech, Inc., South San Francisco, CA, and James K. Chen, Stanford School of Medicine, Stanford, CA

Systems Biology and Signaling Networks

Functional genomics of oncogenic ras signaling
Alejandro Sweet-Cordero

Single-cell expression heterogeneities identified by stochastic sampling
Kevin Janes, University of Virginia, Charlottesville, VA

Single cell analysis of the differential regulation of p53 dynamics
Eric Batchelor, Harvard Medical School, Boston, MA

Targeting mTOR to Inhibit Cancer Cell Growth and Cell Cycle

Overview of mTOR pathway: New and old signaling mechanisms
Feng Hong, University of Miami School of Medicine, Miami, FL

mTOR pathway components as therapeutic targets: Preclinical and recent clinical experience
Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX

mTOR pathway: New insights and rational combinations for overcoming resistance mechanisms
Joyce M. Slingerland

Fusion Proteins in Hematologic Malignancies: MLL and Company

MLL: Why so much “company”?
Janet D. Rowley

Lessons learned from yeast about human leukemia
Ali Shilatifard, Stowers Institute for Medical Research, Kansas City, MO

Therapeutic targets in MLL-associated leukemia
Michael Thirman, University of Chicago, Chicago, IL

HER2-Targeting Therapies, Resistance, and Counter-acting Strategies

Rationally designed targeted therapies to overcome herceptin resistance
Dihua Yu

Novel and not so novel biomarkers of response and resistance to inhibitors of HER2 (ErbB2)
Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA

Modern clinical trials attempting to bridge the gap between the clinic and the lab
Martine J. Piccart-Gebhart, Jules Bordet Institute, Brussels, Belgium

Notch Signaling: Finding New Targets of Cancer Treatment

Notch signaling and cancer
Tong Dai

Targeting notch in cancer: Opportunities and challenges
Jon C. Aster, Brigham and Women’s Hospital, Boston, MA

Building a rational strategy for notch targeting in breast cancer
Lucio Miele, Loyola University Chicago, Maywood, IL